ATE50913T1 - Impfstoff gegen hundecoronavirus. - Google Patents

Impfstoff gegen hundecoronavirus.

Info

Publication number
ATE50913T1
ATE50913T1 AT84902632T AT84902632T ATE50913T1 AT E50913 T1 ATE50913 T1 AT E50913T1 AT 84902632 T AT84902632 T AT 84902632T AT 84902632 T AT84902632 T AT 84902632T AT E50913 T1 ATE50913 T1 AT E50913T1
Authority
AT
Austria
Prior art keywords
vaccine against
against dog
coronavirus
canine coronavirus
dog coronavirus
Prior art date
Application number
AT84902632T
Other languages
English (en)
Inventor
William M Acree
Bobby Edwards
John W Black
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27054825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE50913(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/504,434 external-priority patent/US4567043A/en
Application filed by American Home Prod filed Critical American Home Prod
Application granted granted Critical
Publication of ATE50913T1 publication Critical patent/ATE50913T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/215Coronaviridae, e.g. avian infectious bronchitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14311Parvovirus, e.g. minute virus of mice
    • C12N2750/14334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18411Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/818Viral vaccine for canidae or mustelidae, e.g. dogs, foxes, minks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT84902632T 1983-06-15 1984-06-14 Impfstoff gegen hundecoronavirus. ATE50913T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US06/504,434 US4567043A (en) 1983-06-15 1983-06-15 Canine corona virus vaccine
US06/618,638 US4567042A (en) 1983-06-15 1984-06-07 Inactivated canine coronavirus vaccine
EP84902632A EP0145783B2 (de) 1983-06-15 1984-06-14 Impfstoff gegen hundecoronavirus
PCT/US1984/000904 WO1985000014A1 (en) 1983-06-15 1984-06-14 Canine coronavirus vaccine

Publications (1)

Publication Number Publication Date
ATE50913T1 true ATE50913T1 (de) 1990-03-15

Family

ID=27054825

Family Applications (4)

Application Number Title Priority Date Filing Date
AT89201996T ATE280217T1 (de) 1983-06-15 1984-06-14 Hundecoronavirus
AT84902632T ATE50913T1 (de) 1983-06-15 1984-06-14 Impfstoff gegen hundecoronavirus.
AT89201017T ATE103181T1 (de) 1983-06-15 1989-04-20 Tieraerztliche impfstoffe.
AT89202001T ATE103180T1 (de) 1983-06-15 1989-07-31 Impfstoff-zubereitung.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT89201996T ATE280217T1 (de) 1983-06-15 1984-06-14 Hundecoronavirus

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT89201017T ATE103181T1 (de) 1983-06-15 1989-04-20 Tieraerztliche impfstoffe.
AT89202001T ATE103180T1 (de) 1983-06-15 1989-07-31 Impfstoff-zubereitung.

Country Status (7)

Country Link
US (1) US4567042A (de)
EP (4) EP0145783B2 (de)
AT (4) ATE280217T1 (de)
DE (4) DE3486495D1 (de)
ES (1) ES8604422A1 (de)
NL (1) NL940017I2 (de)
WO (1) WO1985000014A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990367A (en) * 1987-03-09 1991-02-05 Diamond Scientific Company Canine distemper virus vaccine
US5565209A (en) * 1987-03-17 1996-10-15 Akzo Nobel N.V. Adjuvant mixture
EP0283085B1 (de) * 1987-03-17 1992-11-11 Akzo N.V. Adjuvanzienmischung
US4904468A (en) * 1987-06-08 1990-02-27 Norden Laboratories, Inc. Canine coronavirus vaccine
US5911999A (en) * 1987-09-28 1999-06-15 Pfizer, Inc. Vaccine based on TGEV for protection of dogs against canine coronavirus
US5232694A (en) * 1989-05-03 1993-08-03 Akzo N.V. Canine corona virus vaccine
US5672350A (en) * 1989-08-22 1997-09-30 Veterinary Infectious Disease Organization Recombinant bovine coronavirus E2 and E3 polypeptides and vaccines
US6004563A (en) * 1990-11-07 1999-12-21 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
US6057436A (en) * 1990-11-14 2000-05-02 Pfizer Inc. Canine coronavirus S gene and uses therefor
US6372224B1 (en) 1990-11-14 2002-04-16 Pfizer Inc. Canine coronavirus S gene and uses therefor
PT510773E (pt) * 1991-04-25 2004-04-30 Akzo Nobel Nv Vacina subunidade do coronavirus canino
US5750112A (en) * 1993-02-26 1998-05-12 Solvay Animal Health, Inc. Canine coronavirus vaccine from feline enteric coronavirus
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
US20040048235A1 (en) * 1995-08-29 2004-03-11 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
GB9622159D0 (en) * 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
US6093564A (en) 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
US6617100B2 (en) 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
US20020131958A1 (en) * 2001-01-22 2002-09-19 John Chapman Method for purifying a biological composition
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
CA2510189A1 (en) * 2002-12-19 2004-07-08 Thomas Gore Trivalent vaccine with maternal antibody transfer via the milk
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
HRP20050660A2 (en) * 2003-01-29 2006-02-28 Pfizer Products Inc. Canine vaccines against bordetella bronchiseptica
GB0315323D0 (en) * 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
CN1918281A (zh) * 2003-10-23 2007-02-21 辉瑞产品公司 牙周病疫苗
AU2006231916A1 (en) * 2005-04-07 2006-10-12 Pharmacia & Upjohn Company Llc Formulations and process for production of Bordetella bronchiseptica p68 antigen and vaccines
DE602005025649D1 (de) * 2005-10-26 2011-02-10 Canio Buonavoglia Pantropisches Hundecoronavirus
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
KR101013226B1 (ko) * 2008-05-14 2011-02-10 녹십자수의약품(주) 개 바이러스성 설사병 예방용 백신
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
UY34745A (es) 2012-04-18 2013-11-29 Zoetis Llc Vacunas y procedimientos para tratar la enfermedad de lyme en perros
US20140170180A1 (en) 2012-12-17 2014-06-19 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5a, methods of use and vaccine
US20140234354A1 (en) 2013-02-15 2014-08-21 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5b, methods of use and vaccine
US9579373B2 (en) 2013-03-15 2017-02-28 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
CN113924111A (zh) 2019-01-04 2022-01-11 勃林格殷格翰动物保健美国公司 减毒的支气管败血性博德特菌菌株、包含该减毒的菌株的口服疫苗及其制备和使用方法
CN109765384B (zh) * 2019-01-29 2022-11-18 北京勤邦生物技术有限公司 一种犬冠状病毒抗体荧光检测试纸条及其制备方法和应用
CN112402599B (zh) * 2019-08-23 2023-06-27 中国农业科学院特产研究所 一种犬用犬瘟热、细小病毒病二联灭活疫苗及其制备方法
CA3194830A1 (en) * 2020-10-08 2022-04-14 Paula WALKER Methods and apparatuses for detecting respiratory infections
JPWO2022149342A1 (de) * 2021-01-06 2022-07-14

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3143474A (en) * 1962-07-30 1964-08-04 Sterling Drug Inc Preparation of duck-embryo modified infectious canine hepatitis virus vaccine
US3704203A (en) 1967-08-24 1972-11-28 Diamond Lab Inc Transmissible gastroenteritis vaccines and methods of producing the same
US3652761A (en) * 1969-09-04 1972-03-28 Corning Glass Works Immunochemical composites and antigen or antibody purification therewith
US3959251A (en) * 1970-06-25 1976-05-25 Exploaterings Aktiebolaget T.B.F. Stabilized agar product and method for its stabilization

Also Published As

Publication number Publication date
EP0344872B1 (de) 1994-03-23
NL940017I1 (nl) 1994-10-17
NL940017I2 (nl) 2001-02-01
ES8604422A1 (es) 1986-02-01
EP0145783B2 (de) 2004-01-02
EP0344872A1 (de) 1989-12-06
DE3486292T2 (de) 1994-06-30
DE3486293D1 (de) 1994-04-28
EP0345911B1 (de) 2004-10-20
US4567042A (en) 1986-01-28
WO1985000014A1 (en) 1985-01-03
DE3486293T4 (de) 1995-06-14
DE3486293T3 (de) 2002-11-21
EP0345911A1 (de) 1989-12-13
EP0329264A2 (de) 1989-08-23
EP0145783B1 (de) 1990-03-14
ES538588A0 (es) 1986-02-01
ATE103180T1 (de) 1994-04-15
DE3486292D1 (de) 1994-04-28
DE3486495D1 (de) 2004-11-25
EP0329264B1 (de) 1994-03-23
ATE103181T1 (de) 1994-04-15
DE3481582D1 (de) 1990-04-19
EP0344872B2 (de) 2002-04-24
ATE280217T1 (de) 2004-11-15
DE3486293T2 (de) 1994-06-30
EP0329264A3 (en) 1989-12-13
EP0145783A4 (de) 1985-10-14
EP0145783A1 (de) 1985-06-26

Similar Documents

Publication Publication Date Title
ATE50913T1 (de) Impfstoff gegen hundecoronavirus.
PT714444E (pt) Atenuacao de um epitopo imunodominante de um antigenio para utilizacao em vacinas e imunoterapias para plantas, animais e homens
DE69009071D1 (de) Künstliche Lunge.
MX9100067A (es) Nuevos usos de l-deprenil y composiciones para los mismos
ATE82509T1 (de) Orale impfstoffe.
DE69202790D1 (de) Futter und Futterzusatzmittel mit einer verbesserten Resistenz gegen Krankheiten wie Pseudorabies für Vieh, Geflügel und Fisch.
NO882500D0 (no) Hunde-coronavirus-vaksine.
SE7512828L (sv) Calicivirusvaccin
JPS5663922A (en) Feline infectious peritonitis virus* vaccine obtained therefrom* its manufacture and use
ATE5682T1 (de) Veterinaere impfstoffe gegen pasteurellose.
KR830005871A (ko) 광견병 백신의 제조방법
SE429595B (sv) Anordning for att uppfoda, kvarhalla och goda i vatten levande djur, i synnerhet fiskar
ES2089891T3 (es) Comprimido veterinario especialmente destinado a los gatos.
FI833770A7 (fi) Orgaanisia yhdisteitä ja niiden käyttö lääkkeinä.
KR900017611A (ko) 개의 코로나 바이러스 백신
ES2063048T3 (es) Vacuna para proteccion de gatos contra la peritonitis infecciosa felina.
ATE137409T1 (de) Atmungskrankheitimpfstoff für katzen
ATE16348T1 (de) Ozon-inaktivierte keime als vakzine.
DE59602588D1 (de) Vorrichtung zum elektrischen Betäuben von Schlachttieren
DK233188D0 (da) Pyrrolophenylalkanolaminer, fremgangsmaader til deres fremstilling samt deres anvendelse som ydelsesfremmende midler til dyr
ES263684Y (es) "jaula de pisos perfeccionada, para la cria y recria en avicultura".
SE8100489L (sv) Sett att framstella en lettblastbetong med hog ballasthalt
KR880015574U (ko) 농작물 유해 조수 퇴치용 모형새
PL206024A1 (pl) Torf jako pasza w zywieniu zwierzat domowych i drobiu
ES262322Y (es) "dispositivo impulsor de aire para mantener objetos en flotacion".

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time
UEP Publication of translation of european patent specification

Ref document number: 0145783

Country of ref document: EP